Trinity Biotech Appoints New Biosensor Marketing Director
Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company at the forefront of human diagnostics and diabetes management solutions, including wearable biosensors, has announced the appointment of David Ouston as its new Biosensor Marketing Director. Mr. Ouston brings extensive commercial experience, having successfully driven the growth of glucose monitoring devices for major companies in global markets.
Leadership Insights
John Gillard, President and CEO of Trinity Biotech, shared his thoughts, stating, “Our commitment to innovative, needle-free, reusable continuous glucose monitoring (CGM) technology remains a key long-term growth driver for Trinity Biotech. We are excited to welcome David to our team as a strategic addition to help advance this mission. His vast experience in global leadership and market access strategies for diabetes management devices and digital solutions will be invaluable as we prepare to launch our own CGM in the rapidly expanding diabetes and wellness markets.”
David Ouston’s Perspective
Upon his appointment, Mr. Ouston expressed, “I am excited to join Trinity Biotech and contribute to its vision of making CGM technology accessible and innovative in markets around the world. Trinity’s device represents a significant advancement in wearable biosensor technology and wellness analytics, which can enhance public health for many people globally. I look forward to collaborating with this talented team to deliver a truly transformative and valuable solution to the global market.”
David Ouston’s Background
Mr. Ouston brings 16 years of experience in the glucose monitoring and diabetes health sectors. He has held global and EMEA regional marketing positions at Johnson & Johnson and LifeScan, where he played a key role in driving innovations within the OneTouch glucose monitoring portfolio. Prior to that, he worked in marketing for a private healthcare provider, promoting their global healthcare brand. Mr. Ouston earned a Bachelor of Arts Degree in Business Administration from Brunel University in the U.K.
About Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology firm dedicated to human diagnostics and diabetes management solutions, which includes wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for both point-of-care and clinical laboratory segments. Recently, Trinity Biotech has ventured into the wearable biosensor industry, aiming to create a variety of biosensor devices and related services, beginning with a continuous glucose monitoring product. Their products are utilized to detect infectious diseases and measure Hemoglobin A1c levels, along with other chemistry parameters in serum, plasma, and whole blood. Trinity Biotech operates directly in the United States and through a network of international distributors and strategic partners.
Contact Information
If you have any inquiries, please reach out to:
Trinity Biotech plc
Gary Keating
Phone: (353)-1-2769800
LifeSci Partners, LLC
Eric Ribner
Phone: (1)-646-751-4363
Email: investorrelations@trinitybiotech.com
RedChip Companies Inc.
Dave Gentry, CEO
Phone: (1)-407-644-4256
Email: TRIB@redchip.com
Frequently Asked Questions
What is the primary focus of Trinity Biotech?
Trinity Biotech specializes in human diagnostics and diabetes management solutions, including wearable biosensors.
Who has been appointed as the new Marketing Director?
David Ouston has been appointed as the Biosensor Marketing Director.
What is the significance of the new appointment?
David Ouston brings extensive experience in advancing glucose monitoring devices, which will be crucial for the rollout of new products.
What are Trinity Biotech's future plans?
Trinity Biotech aims to develop a variety of biosensor devices and services, starting with a continuous glucose monitoring product.
How can I contact Trinity Biotech for more information?
You can reach out to Trinity Biotech plc or LifeSci Partners using the contact details provided above.
